Research Participation
Client Portal
Talk to an expert
Go Back

Rheumatology

Rheumatology is back in motion, and the intelligence gap between brands that see it coming and brands that do not has never been wider.

Subscribe for Rheumatology updates

About Rheumatology

After years of relative stability, rheumatology has re-entered a period of rapid commercial evolution. The SLE pipeline is rich with innovative mechanisms and high-potential line extensions resonating strongly with specialists. New product launches in lupus nephritis and recent advances in cutaneous lupus are expanding the treatment landscape, and cell therapies, with potential across the broader rheumatic spectrum, are creating a new category of commercial questions that did not exist three years ago.

Spherix provides insights to 9 of the top 10 global pharmaceutical companies in rheumatology, drawing on more than 30 years of combined team experience and established relationships with the world’s leading rheumatology KOLs. Our community of practicing rheumatologists spans the full range of indications Spherix tracks, from high-volume RA and PsA to the rarer and rapidly evolving SLE, SSc, and IIM landscapes. Spherix’s research excellence has been recognized at ACR, including a 2024 SLE abstract selected among the best presented at the conference and 35+ studies published annually.

Spherix rheumatology intelligence is a go-to resource for leading brands, industry media, and financial analysts covering the space.
INDICATIONS COVERED
  • Ankylosing Spondylitis and nr-AxSpA
  • Cutaneous Lupus Erythematosus (CLE)
  • Cell Therapies in Rheumatology
  • Giant Cell Arteritis (GCA)
  • Idiopathic Inflammatory Myopathies (IIM)
  • Interstitial Lung Disease (ILD)
  • Lupus Nephritis (LN)
  • Polymyalgia Rheumatica (PMR)
  • Psoriatic Arthritis (PsA)
  • Rheumatoid Arthritis (RA)
  • Sjögren's Disease (SjD)
  • Systemic Lupus Erythematosus (SLE)
  • Systemic Sclerosis (SSc)

The insights that inform confident, strategic decisions

The Spherix three-perspective lens applied to rheumatology:

physician
How are rheumatologists approaching patient selection and sequencing in SLE and LN as new mechanisms arrive? Where is prescribing intent shifting in PsA and RA as the biologic class matures and cell therapies emerge?
PHYSICIAN INSIGHT
Patient
What are lupus and systemic sclerosis patients reporting about treatment burden, disease management, and quality of life that clinical trial data does not surface?
PATIENT INSIGHT
PAYER (MARKET ACCESS
How are payers managing formulary placement and coverage criteria across rheumatic conditions as the pipeline expands — and where are access barriers forming ahead of key launches?
PAYER INSIGHT

Spherix clients have exclusive access to

talk to an expert
Research products
Continuously updated syndicated intelligence across provider, patient, and payer perspectives – with advanced report release for subscribed clients ahead of general availability.
Therapeutic expertise and advisory
Direct access to Spherix rheumatology specialists for strategic working sessions, commercial pressure-testing, and on-demand advisory – the expertise behind the research, available to your team when you need it.
Customization and targeting
Proprietary questions embedded in research waves specific to your brand or pipeline asset. Custom data cuts and commercially relevant analyses on request. Target list matching with prescriber group analysis.
AI-assisted synthesis

Every output is reviewed and validated by a rheumatology specialist before delivery. Spherix's AI-assisted intelligence layer draws on more than a decade of rheumatology data simply to get that specialist to an answer faster, and to help identify the right rheumatologists for every wave.

Related Articles

VIEW ALL NEWS & MEDIA
Rheumatology   •   Press Release

Bimzelx Momentum Builds as Rheumatologists Look Beyond TNFs to the Next Wave of axSpA Therapies, According to Spherix Global Insights

Rheumatology   •   Press Release

Sotyktu Begins Defining a New Oral Treatment Segment in Psoriatic Arthritis, According to Spherix Global Insights Launch Research

Rheumatology   •   Press Release

Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain

Rheumatology   •   Press Release

CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need

Meet the Team

Lynn has over 10 years at Spherix, leading strategic initiatives and insights development. She previously directed research analytics at Decision Resources Group and managed immunology research at BioTrends Research Group, with extensive experience in data analysis and client relations in the biopharmaceutical sector.
Lynn Price
Lynn PriceFranchise Head, Rheumatology
Ryan delivers data-driven perspectives across rheumatology and specialty healthcare markets. He specializes in translating the voice of healthcare providers into actionable insights that inform brand strategy, market access, and commercial decision-making. With experience spanning market research, client strategy, consumer insights, and business development, Ryan has authored thought leadership on evolving treatment landscapes, stakeholder behavior, and product launch dynamics. He is particularly focused on competitive positioning and the factors shaping physician treatment adoption within the rheumatology landscape. Ryan holds a BS from Northeastern University and a Graduate Certificate in Marketing Strategy from Cornell University.
Ryan Rex
Ryan RexInsights Director, Rheumatology
Sawyer delivers data-driven perspectives across rheumatology markets. He specializes in translating the voice of healthcare providers into actionable insights that inform brand strategy, market access, and commercial decision-making. Sawyer has coauthored thought leadership, including white papers on evolving treatment landscapes and product launch dynamics in complex autoimmune conditions. He holds a bachelor’s degree in Economics from the University of Notre Dame.
Sawyer May
Sawyer MayInsights Director, Rheumatology